DAX24.295 +0,1%Est505.739 -0,1%MSCI World4.343 -0,1%Top 10 Crypto11,56 -0,1%Nas23.429 +0,5%Bitcoin74.236 -1,3%Euro1,1788 +0,2%Öl62,07 ±0,0%Gold4.483 +0,9%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Tesla A1CX3T TUI TUAG50 Lufthansa 823212 Deutsche Telekom 555750 Siemens Energy ENER6Y Bayer BAY001 Allianz 840400 D-Wave Quantum A3DSV9 RENK RENK73 Infineon 623100 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX stabil -- Asiens Börsen wenig bewegt -- Novo Nordisk erhält US-Zulassung für Wegovy-Tabletten -- Alphabet kauft Intersect -- DroneShield, Rüstungsaktien, Mercedes-Benz, Bitcoin, Gold im Fokus
Top News
Bilanzen: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison Bilanzen: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison
Vorweihnachtliche Zurückhaltung: DAX kommt kaum vom Fleck Vorweihnachtliche Zurückhaltung: DAX kommt kaum vom Fleck
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Merck Aktie

Kaufen
Verkaufen
Merck Aktien-Sparplan
88,70 EUR +1,10 EUR +1,26 %
XETRA
104,53 USD -0,20 USD -0,19 %
nachbörslich
BTT
Merck jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.212,98 Mrd. EUR

KGV14,77Div. Rendite3,14%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0YD8Q

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS58933Y1055

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolMRK

Merck Aktien News

DatumMeistgelesen
ZacksEarnings Season Scorecard and Fresh Analyst Reports for Chevron, Merck & Others
ZacksMerck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
ZacksMerck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
BenzingaPrice Over Earnings Overview: Merck & Co
ZacksMerck (MRK) Outpaces Stock Market Gains: What You Should Know
BenzingaUnpacking the Latest Options Trading Trends in Merck & Co
BenzingaMerck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
Business TimesChina’s WuXi Biologics to sell vaccine facility to Merck for US$500 million
ZacksMerck (MRK) Rises Higher Than Market: Key Facts
ZacksMerck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
ZacksMerck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
MotleyFool2 Reasons to Sell Merck Stock and 1 Reason to Buy
ZacksMerck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
BenzingaBig Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
MotleyFoolIs Merck the Next Big Weight-Loss Stock?
Korea TimesMerck to invest $73 mil. in materials development center in Japan
ZacksMerck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...
PR NewswireElanco Completes Sale of Aqua Business
PR NewswireASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
PR NewswireHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
PR NewswireHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
PR NewswireHealth Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcino...
PR NewswireHealth Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcino...
PR NewswireFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
PR NewswireHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or ...
PR NewswireHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or ...
PR NewswireMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
PR NewswireMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
PR NewswireElanco Announces Sale of Aqua Business for $1.3 Billion
PR NewswireMerck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR

Merck News

Merck News: auf dieser Seite finden Sie alle Merck News und Nachrichten zur Merck Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merck News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merck News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.